APOE4 APOE Missense Variant Linked to Increased Alzheimer's Disease Risk in African Americans A case-control study found that the APOE ε3[R145C] variant, seen in 4 percent of African Americans, increases AD risk in individuals with the ε3/ε4 genotype. Protective, Risk-Linked APOE Alleles Affect Glial Cell Transcriptome The APOEε4 allele is linked to the upregulation of a phagocytosis and proinflammatory gene set both in normal aging and Alzheimer's disease brains. Genetic Risk of Cognitive Decline Varies Between Latino Populations, Study Finds The APOE-ε4 allele, a major genetic risk factor for Alzheimer's disease, conveys more risk among Cuban than other Latino populations, the analysis found. Alzheimer's Disease Risk Linked to Noncoding Variants in APOE Region The researchers not only tied a variant near TOMM40 to Alzheimer's disease, but also two variants not previously implicated in risk for the disease. NIH Grants $4.8M for Mulit-Omic Study of ApoE4 in Alzheimer's Disease Gladstone Institutes researchers will use proteomic, genomic, and gene-altering approaches to investigate apoe4 toxicity as part of a five-year project. Jun 10, 2019 Alzheimer's Disease Potential Risk Variants Identified in Study of APOE4 Carriers, Noncarriers May 31, 2018 Functional Characterization of Alzheimer's Disease APOE4 Variant Shows How it Changes Brain Cells Jan 11, 2018 Combined Genotyping, CT Scan Model Predicts Risk of Stroke Recurrence Mar 3, 2016 APOE Sequencing Confirms Previous Markers of Longevity, Implicates Regulatory Variants Jan 20, 2016 Alzheimer's-Related ApoE4 Acts as Transcription Factor to Lead to Disease Jul 24, 2015 ACMG Recommendations Aim to Spark Physician, Patient Discussion on Genetic Testing Premium Jul 21, 2015 Duke Researchers Present New Data on APOE/TOMM40 Algorithm for Alzheimer's MCI Risk Premium Jul 25, 2012 Rodent Study Suggests Low-Dose Pioglitazone May Improve Cognitive Function in Alzheimer's Patients Premium May 23, 2012 Genentech Takes Personalized Medicine Approach in Pursuing Amyloid Hypothesis for Alzheimer's Drug Premium Apr 27, 2011 Duke University Keeping an Eye on DTC Genomics Firms that Might be Infringing its APOE Patents Premium Apr 20, 2011 Adding Alzheimer's Risk Option, 23andMe Revives Questions on Utility of DTC Genomics Premium Jan 12, 2011 Takeda to Use Zinfandel's TOMM40 Test in Alzheimer's Development Program for Actos Premium Jul 14, 2010 Brain Imaging, Cognitive Evaluation Link TOMM40 Alterations to Alzheimer's Risk in Healthy Patients Premium Jan 6, 2010 Researchers Publish Data on Gene Variant Associated with Late-Onset Alzheimer's Disease Premium Sep 9, 2009 Avey Leaves 23andMe to Start Alzheimer's Research Foundation Using DTC Genomics Firm's Platform Premium Jul 15, 2009 Accera Presents New Pharmacogenomics Data on Medical Food Product for Alzheimer's Disease Premium Breaking News SEC Concludes CareDx Investigation, Recommends No Enforcement Action Streck Quality Controls for DiaSorin's Luminex Sepsis Tests Receive FDA Clearance Adela Closes $48M Financing to Develop Cancer Monitoring, Early Detection Test 3EO Health At-Home Molecular COVID-19 Test Nabs FDA EUA Top Five Articles on GenomeWeb Last Week: IVDR Rollout, AI in Genomics, 10x vs. NanoString, More The Scan Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants. Small Study of Gene Editing to Treat Sickle Cell Disease In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms. Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema. Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.